GGrantIndex
← Search

ENHANCING THE IMMUNOGENICITY OF NECTIN-4 TARGETED THERAPY FOR THE TREATMENT OF AGGRESSIVE BLADDER CANCER

$707,437FY2022Department of the ArmyDOD

Sloan-Kettering Institute For Cancer Research

Investigators

View source on USAspending →
ENHANCING THE IMMUNOGENICITY OF NECTIN-4 TARGETED THERAPY FOR THE TREATMENT OF AGGRESSIVE BLADDER CANCER · GrantIndex